生物技术通报 ›› 2022, Vol. 38 ›› Issue (3): 181-187.doi: 10.13560/j.cnki.biotech.bull.1985.2021-0630

• 研究报告 • 上一篇    下一篇

乳双歧杆菌V9对高脂饮食诱导的NAFLD大鼠的改善作用

钟明月1(), 刘春妍1, 颜妍1, 张晓慧1, 原海升1, 徐国全1, 张和平2, 王玉珍1()   

  1. 1.内蒙古农业大学生命科学学院,呼和浩特 010011
    2.内蒙古农业大学教育部乳品生物技术与工程重点实验室,呼和浩特 010018
  • 收稿日期:2021-05-17 出版日期:2022-03-26 发布日期:2022-04-06
  • 作者简介:钟明月,男,硕士研究生,研究方向:生物化学与分子生物学;E-mail: 627401932@qq.com
  • 基金资助:
    国家自然科学基金项目(81560677);内蒙古自治区高等学校青年科技英才(NJYT-19-A14)

Improvement Effect of Bifidobacterium lactis V9 on NAFLD Rats Induced by High-fat Diet

ZHONG Ming-yue1(), LIU Chun-yan1, YAN Yan1, ZHANG Xiao-hui1, YUAN Hai-sheng1, XU Guo-quan1, ZHANG He-ping2, WANG Yu-zhen1()   

  1. 1. College of Life Sciences,Inner Mongolia Agricultural University,Hohhot 010011
    2. Key Laboratory of Dairy Biotechnology and Engineering,Ministry of Education,Inner Mongolia Agricultural University,Hohhot 010018
  • Received:2021-05-17 Published:2022-03-26 Online:2022-04-06

摘要:

研究乳双歧杆菌V9(V9)对高脂饮食诱导的非酒精性脂肪肝疾病(NAFLD)大鼠脂代谢、肠道损伤的改善作用,并探讨其作用机制。雄性Wistar大鼠随机分为5组:空白对照组(Control)、高脂饮食模型组(HFD)、黄连素阳性药物组(Berberine)、乳双歧杆菌V9治疗组(HFD/V9)和乳双歧杆菌V9对照组(V9)。除Control和V9给予普通维持饲料外,其他给予高脂饮食6周构建NAFLD模型。6周后,将高脂饮食替换为普通维持饲料,大鼠灌胃给予乳双歧杆菌V9(1×109CFU/mL)或黄连素(50 mg/kg)。4周后,收集血液、肝脏以及结肠组织用于后续试验检测。与Control组相比,HFD组中肝脏非酯化脂肪酸(NEFA)、甘油三酯(TG)、肝脏脂肪酸合成酶(FAS)和肝脏脂肪酸结合蛋白1(Fabp1)mRNA的表达明显增高(P<0.01);同时,肠道细胞因子白介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)、Toll-样受体2(TLR2)和Toll-样受体9(TLR9)的mRNA表达在HFD模型组中也明显升高(P<0.01);相反地,紧密连接蛋白ZO-1和occludin mRNA的表达在HFD模型组中明显降低(P<0.01)。在给予乳双歧杆菌V9治疗以后,肝脏NEFA和TG含量明显降低(P<0.01);肝脏FAS和Fabp1的mRNA表达也显著降低(P<0.01)。乳双歧杆菌V9和黄连素治疗后都降低了肠道IL-1β、TNF-α、TLR2和TLR9的转录水平(P<0.01)。但是,提高了肠道紧密连接蛋白ZO-1和occludin mRNA的表达。Control组和V9组二者效应无显著差异(P<0.01)。HE染色显示,以上各组的结肠病理学无明显差异。益生乳双歧杆菌 V9 可以通过缓解脂代谢紊乱、降低肠道炎症反应并改善肠道黏膜屏障结构,从而改善高脂饮食诱导的 NAFLD。

关键词: 肠道菌群, 非酒精性脂肪肝病, 益生菌, 高脂饮食

Abstract:

This work aims to study the effect of probiotic Bifidobacterium lactis V9(V9)on lipid metabolism and intestinal injury in non-alcoholic fatty liver disease(NAFLD)rats induced by high-fat diet,and to explore its mechanism. Male Wistar rats were randomly divided into 5 groups(n=8):blank control group(Control),high-fat diet model group(HFD),berberine-positive drug group(Berberine),the probiotic B. lactis V9 treatment group(HFD/V9),and the probiotic B. lactis V9 control group(V9). Except Control and V9 were given ordinary maintenance feed,others were given a high-fat diet for 6 weeks to construct a NAFLD model. After 6 weeks,the high-fat diet was replaced with ordinary maintenance feed,and the rats were given probiotic B. lactis V9(1×10 9CFU/mL)or berberine(50 mg/kg)by gavage. After 4 weeks,blood,liver and colon tissues were collected for follow-up testing. Compared with the Control group,the mRNA expressions of liver non-esterified fatty acids(NEFA),triglycerides(TG),liver fatty acid synthase(FAS)and liver fatty acid binding protein 1(Fabp1)in the HFD group significantly increased(P<0.01). At the same time,mRNA expressions of the intestinal cytokine interleukin 1β(IL-1β),tumor necrosis factor α(TNF-α),Toll-like receptor 2(TLR2)and Toll-like receptor 9(TLR9)in the HFD model group also significantly increased(P<0.01). On the contrary,the expression of tight junction protein ZO-1 and occludin mRNA in the HFD model group significantly decreased(P<0.01). After treatment with probiotic B. lactis V9,the contents of NEFA and TG in the liver significantly reduced(P<0.01),the mRNA expressions of FAS and Fabp1 in the liver also significantly reduced(P<0.01). Both probiotic B. lactis V9 and berberine treatment reduced the transcription levels of intestinal IL-1β,TNF-α,TLR2 and TLR9(P<0.01),which increased the expressions of intestinal tight junction proteins ZO-1 and occludin mRNA. HE staining showed that there was no significant difference in colonic pathology among the above groups. Probiotic Probiotics B. lactis V9 can improve NAFLD induced by high-fat diet by alleviating lipid metabolism disorders,reducing intestinal inflammation and improving mulosal barrier.

Key words: intestinal microflora, non-alcoholic fatty liver disease, probiotics, high fat diet